Nascent Biotech, Inc. (NBIO)
USD 0.01
(44.44%)
USD 0.01
(44.44%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -2.22 Million USD | -3.44% |
| 2023 | -2.15 Million USD | -371.67% |
| 2022 | -457.05 Thousand USD | 67.36% |
| 2021 | -1.4 Million USD | 59.38% |
| 2020 | -3.44 Million USD | -151.82% |
| 2019 | -1.36 Million USD | 38.38% |
| 2018 | -2.22 Million USD | -255.65% |
| 2017 | 1.42 Million USD | 126.22% |
| 2016 | -5.44 Million USD | -153.85% |
| 2015 | -2.14 Million USD | -275.35% |
| 2014 | -571.4 Thousand USD | 15.26% |
| 2013 | -674.31 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q4 | -516.03 Thousand USD | -41.6% |
| 2024 Q3 | -364.42 Thousand USD | 56.48% |
| 2024 Q1 | -511.97 Thousand USD | 5.16% |
| 2024 FY | -2.22 Million USD | -3.44% |
| 2024 Q2 | -837.45 Thousand USD | -63.57% |
| 2023 Q2 | -521.23 Thousand USD | 15.89% |
| 2023 Q1 | -619.67 Thousand USD | -49.33% |
| 2023 FY | -2.15 Million USD | -371.67% |
| 2023 Q4 | -539.82 Thousand USD | -13.64% |
| 2023 Q3 | -475.02 Thousand USD | 8.86% |
| 2022 Q2 | -230.23 Thousand USD | 48.01% |
| 2022 FY | -457.05 Thousand USD | 67.36% |
| 2022 Q1 | -442.8 Thousand USD | -265.89% |
| 2022 Q3 | 630.97 Thousand USD | 374.05% |
| 2022 Q4 | -414.98 Thousand USD | -165.77% |
| 2021 Q2 | -561 Thousand USD | -1.75% |
| 2021 Q1 | -551.34 Thousand USD | 77.75% |
| 2021 FY | -1.4 Million USD | 59.38% |
| 2021 Q4 | 266.92 Thousand USD | 148.1% |
| 2021 Q3 | -554.93 Thousand USD | 1.08% |
| 2020 FY | -3.44 Million USD | -151.82% |
| 2020 Q3 | -368.23 Thousand USD | -12.43% |
| 2020 Q2 | -327.52 Thousand USD | -19.65% |
| 2020 Q1 | -273.74 Thousand USD | 18.2% |
| 2020 Q4 | -2.47 Million USD | -572.89% |
| 2019 Q1 | -439.72 Thousand USD | 45.12% |
| 2019 Q4 | -334.63 Thousand USD | -30.43% |
| 2019 Q3 | -256.57 Thousand USD | 24.09% |
| 2019 FY | -1.36 Million USD | 38.38% |
| 2019 Q2 | -338.01 Thousand USD | 23.13% |
| 2018 Q1 | -298.54 Thousand USD | -108.99% |
| 2018 Q2 | -558.22 Thousand USD | -86.98% |
| 2018 Q3 | -563.67 Thousand USD | -0.98% |
| 2018 FY | -2.22 Million USD | -255.65% |
| 2018 Q4 | -801.31 Thousand USD | -42.16% |
| 2017 Q3 | -569.75 Thousand USD | -135.9% |
| 2017 FY | 1.42 Million USD | 126.22% |
| 2017 Q4 | 3.31 Million USD | 682.57% |
| 2017 Q2 | 1.58 Million USD | 302.03% |
| 2017 Q1 | 394.77 Thousand USD | 166.11% |
| 2016 Q1 | -760.28 Thousand USD | 16.8% |
| 2016 Q4 | -597.19 Thousand USD | -124.78% |
| 2016 Q3 | -265.67 Thousand USD | 93.05% |
| 2016 FY | -5.44 Million USD | -153.85% |
| 2016 Q2 | -3.82 Million USD | -402.61% |
| 2015 Q2 | -323.04 Thousand USD | -27.52% |
| 2015 FY | -2.14 Million USD | -275.35% |
| 2015 Q1 | -253.32 Thousand USD | 31.78% |
| 2015 Q3 | -654.54 Thousand USD | -102.62% |
| 2015 Q4 | -913.83 Thousand USD | -39.61% |
| 2014 Q3 | -65.43 Thousand USD | 7.8% |
| 2014 Q2 | -70.97 Thousand USD | -5.45% |
| 2014 FY | -571.4 Thousand USD | 15.26% |
| 2014 Q4 | -371.36 Thousand USD | -467.54% |
| 2014 Q1 | -67.3 Thousand USD | 0.0% |
| 2013 FY | -674.31 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -66.978% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 55.796% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 87.506% |
| Rebus Holdings, Inc. | -664 Thousand USD | -235.825% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 102.724% |
| Qrons Inc. | -643.67 Thousand USD | -246.428% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -472.395% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 95.983% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -436.701% |
| Skye Bioscience, Inc. | -13.67 Million USD | 83.69% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 96.894% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 145.371% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -751.99% |
| SQZ Biotechnologies Company | -75.82 Million USD | 97.059% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 21.773% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -45.17% |
| Mesoblast Limited | -84.14 Million USD | 97.35% |
| Marizyme, Inc. | -34.08 Million USD | 93.458% |
| Genus plc | 6.4 Million USD | 134.842% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 122.888% |
| Pharming Group N.V. | -4.87 Million USD | 54.301% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -12.253% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -139.417% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 73.295% |
| ContraFect Corporation | -56.88 Million USD | 96.08% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 51.043% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -59.051% |
| IMV Inc. | -38.67 Million USD | 94.234% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 18.938% |
| MultiCell Technologies, Inc. | -722.81 USD | -308401.404% |
| ONE Bio Corp. | 13.68 Million USD | 116.298% |
| Accustem Sciences Inc. | -3.74 Million USD | 40.48% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 96.22% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -361.613% |
| Q BioMed Inc. | -3.44 Million USD | 35.284% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 162.991% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 15.134% |
| Biomind Labs Inc. | -1 Million USD | -120.867% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 95.944% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 23.141% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 66.458% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -19.605% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -7344.842% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 85.949% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -15.382% |
| GB Sciences, Inc. | -1.42 Million USD | -56.977% |
| Alpha Cognition Inc. | -9.7 Million USD | 77.025% |
| HST Global, Inc. | -140.9 Thousand USD | -1482.518% |
| CSL Limited | 3.7 Billion USD | 100.06% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -98.228% |
| Halberd Corporation | -75.05 Thousand USD | -2871.191% |
| Enzolytics Inc. | -2.14 Million USD | -3.773% |
| Agentix Corp. | -1.37 Million USD | -62.557% |
| Resverlogix Corp. | -12.74 Million USD | 82.509% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 29.618% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.475% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -113.59% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 23.62% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -41.189% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 34.511% |
| AVAX Technologies, Inc. | 6.69 Million USD | 133.317% |
| Zenith Capital Corp. | -8.94 Million USD | 75.066% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.464% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -12699.948% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 9.182% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1200.149% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -11.229% |
| Kadimastem Ltd | -3.04 Million USD | 26.655% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -126.602% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -77.538% |
| BioStem Technologies, Inc. | -7.77 Million USD | 71.335% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1128.685% |
| LadRx Corporation | -3.82 Million USD | 41.682% |
| Cell Source, Inc. | -4.32 Million USD | 48.446% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -224.606% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -224.606% |
| NovAccess Global Inc. | -2.46 Million USD | 9.603% |
| Affymax, Inc. | -15.04 Million USD | 85.18% |
| Itoco Inc. | -919.14 Thousand USD | -142.605% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 47.389% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -99.274% |
| Mobile Lads Corp. | -554.55 Thousand USD | -302.106% |
| CytoDyn Inc. | -18.05 Million USD | 87.652% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -8759.273% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -913.222% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -294.862% |
| SYBLEU INC | -149.18 Thousand USD | -1394.757% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -22.769% |
| International Stem Cell Corporation | -663 Thousand USD | -236.332% |
| Bioxytran, Inc. | -3.82 Million USD | 41.628% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -4136.092% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -10863.024% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 93.851% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -37.817% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -203.041% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 28.323% |
| Neutra Corp. | -229.48 Thousand USD | -871.684% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 87.286% |
| PureTech Health plc | -146.19 Million USD | 98.475% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 89.624% |
| IXICO plc | -1.43 Million USD | -55.176% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 76.505% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.169% |
| CSL Limited | 3.81 Billion USD | 100.058% |
| Cellectis S.A. | -108.85 Million USD | 97.952% |